Dr. Ruby Anne Deveras, MD

Dr. Deveras practices at Halifax Health Medical Center of Daytona Beach in Daytona Beach, Florida, part of Halifax Health District.

Dr. Deveras' NPI, 1306844360, was assigned on July 13, 2005. Dr. Deveras graduated from Renaissance School of Medicine at Stony Brook University in 1996. Dr. Deveras holds Florida license ME75526.

Dr. Deveras' primary practice is Halifax Health Medical Center of Daytona Beach, at 303 N Clyde Morris Blvd, Daytona Beach, FL 32114 in Volusia County. The practice phone is (386) 254-4000.

Dr. Deveras' primary practice is Halifax Health Medical Center of Daytona Beach in Daytona Beach, Florida, part of Halifax Health District. Dr. Deveras is also affiliated with AdventHealth Daytona Beach. The medical group on file is Halifax Health. Dmand AI also links Dr. Deveras to 2 more hospitals and 1 behavioral health center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Deveras practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Deveras' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Deveras is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Deveras' licenses on file in 2 states: Florida and District of Columbia.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, fluid and electrolyte imbalances, immune deficiency disease, lung cancer and lymphoma among the conditions Dr. Deveras treats.

CMS data shows 650 Medicare services from Dr. Deveras across 8 procedure codes in 2024, for 309 Medicare patients. Medicare paid $49,745 for them.

CMS counts 309 Medicare patients who saw Dr. Deveras in 2024. The largest group is 75 to 84, with 128 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 10% are also on Medicaid. Their average risk score is 1.92, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Deveras' median patient age at 70, with 76% women.

In 2024, Dr. Deveras wrote 1,308 Medicare Part D claims for 286 patients. 82% of them were for generic drugs. CMS names the drug for 1,009 of them, across 31 drugs with 11 or more claims each, at $1,121,803 in total drug cost. In 2023, CMS named 1,070 claims across 33 drugs.

Dr. Deveras accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Deveras as offering telehealth.

Dmand AI links 7 papers to Dr. Deveras, published from 2011 to 2025. The most frequent topics are Factor VII, Factor VIIa and Hemorrhage. Dr. Deveras' most frequent co-authors are Pamela Parke Carbiener, MD, Rabih C. Fahed, MD and Quinn Jameson Frier, MD.

Dmand AI links Dr. Deveras to 17 clinical trials, 10 of them phase 3 studies. 12 are still active or recruiting. Conditions studied include Breast Neoplasms, Carcinoma, Non-Small-Cell Lung and Carcinoma, Bronchogenic. National Cancer Institute (NCI) sponsors the most, 10.

CMS Open Payments shows 527 general payments to Dr. Deveras from 48 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 59% of the total. Octapharma USA, Inc. paid the most, $6,798.

Dmand AI lists 1 award for Dr. Deveras, most recently CMS Stage 1 EHR in 2013.

Dr. Deveras graduated from Renaissance School of Medicine at Stony Brook University in 1996. Dr. Deveras is a member of ASCO.

Dr. Deveras is in network with 19 carriers, including Elevance, Aetna and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.